Themis, an acronym for thymocyte-expressed molecule involved in selection, is a crucial protein that plays a significant role in the regulation of T cell development and function. Specifically, Themis is integral to the process of T cell receptor (TCR) signaling, which is essential for the proper activation and differentiation of T cells during their development in the thymus. Themis functions by modulating the signaling pathways that are activated following TCR engagement, helping to ensure that T cells are properly educated to distinguish between self and non-self antigens. This is vital for the development of an effective immune response and for preventing autoimmune reactions where the immune system might attack the body's own tissues.
The inhibition of Themis can significantly disrupt T cell development and the immune response. One primary mechanism of Themis inhibition could involve the alteration of its expression levels. Downregulation of Themis, whether through genetic mutations that affect its promoter region or through epigenetic modifications such as DNA methylation or histone changes, can lead to reduced Themis protein in T cells. This reduction can impair the TCR signaling pathway, leading to improper T cell development and potentially resulting in an inadequate immune response to pathogens or failure to maintain self-tolerance. Another potential mechanism for inhibiting Themis is through post-translational modifications that affect its activity or stability. For example, phosphorylation, ubiquitination, or other modifications might alter Themis's interaction with other signaling molecules in the TCR pathway, or they might target Themis for degradation, thereby decreasing its functional availability in the signaling cascade. Understanding the mechanisms by which Themis is inhibited provides important insights into T cell biology and the regulation of immune responses, which could be pivotal for developing therapeutic strategies in immunodeficiency or autoimmune diseases, where T cell function is compromised.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Immunosuppressant that can inhibit calcineurin, influencing TCR signaling. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
Another calcineurin inhibitor, it can modulate TCR-mediated activation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibits Lck and Fyn, Src family kinases involved in TCR signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, it affects AKT activation downstream of TCR. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor; mTOR is a downstream effector in TCR signaling. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-κB inhibitor; TCR signaling can lead to NF-κB activation. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Broad PKC inhibitor; PKC plays a role in TCR-mediated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
P38 MAPK inhibitor; MAPK pathways are downstream of TCR activation. | ||||||